Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$204.79 USD

204.79
516,438

-4.41 (-2.11%)

Updated Nov 29, 2022 04:00 PM ET

After-Market: $204.90 +0.11 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.51%
2Buy17.96%
3Hold9.47%
4Sell5.16%
5Strong Sell2.21%
S&P50010.66%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Biomedical and Genetics

Trades from $1

Balance Sheet

Research for ALNY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Alnylam Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Assets          
Cash & Equivalents 2,436 1,874 1,536 1,084 1,691
Receivables 199 602 43 19 34
Notes Receivable 0 0 0 0 0
Inventories 86 75 56 24 0
Other Current Assets 88 63 80 74 40
Total Current Assets 2,809 2,615 1,716 1,201 1,765
Net Property & Equipment 502 465 425 321 182
Investments & Advances 41 41 15 45 44
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 60 45 18 9 4
Total Assets 3,643 3,407 2,395 1,575 1,995
Liabilities & Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Notes Payable 0 0 0 0 0
Accounts Payable 73 52 50 60 28
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 395 356 197 113 72
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 187 141 78 7 44
Total Current Liabilities 696 585 353 179 144
Mortgages 0 0 0 0 0
Deferred Taxes/Income 152 225 318 58 50
Convertible Debt 0 0 0 0 0
Long-Term Debt 676 191 0 30 30
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,250 1,096 9 5 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,055 2,391 956 273 228
Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 6,058 5,644 5,201 4,175 3,948
Retained Earnings -5,438 -4,585 -3,727 -2,841 -2,148
Other Equity -33 -44 -37 -33 -34
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 588 1,016 1,439 1,302 1,766
Total Liabilities & Shareholder's Equity 3,643 3,407 2,395 1,575 1,995
Total Common Equity 588 1,016 1,439 1,302 1,766
Shares Outstanding 119.60 116.10 111.40 101.10 98.30
Book Value Per Share 4.92 8.75 12.91 12.88 17.97

Fiscal Year End for Alnylam Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2022 6/30/2022 3/31/2022 12/31/2021 9/30/2021
Assets          
Cash & Equivalents 2,265 2,111 2,240 2,436 2,328
Receivables 185 142 157 199 141
Notes Receivable 0 0 0 0 0
Inventories 115 89 79 86 98
Other Current Assets 126 130 115 88 109
Total Current Assets 2,691 2,472 2,590 2,809 2,675
Net Property & Equipment 515 508 504 502 485
Investments & Advances 49 49 41 41 41
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 61 77 70 60 35
Total Assets 3,535 3,330 3,434 3,643 3,472
Liabilities & Shareholders Equity 9/30/2022 6/30/2022 3/31/2022 12/31/2021 9/30/2021
Notes Payable 0 0 0 0 0
Accounts Payable 41 52 55 73 40
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 511 421 356 395 389
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 180 143 154 187 141
Total Current Liabilities 773 658 606 696 611
Mortgages 0 0 0 0 0
Deferred Taxes/Income 133 175 158 152 177
Convertible Debt 1,016 0 0 0 0
Long-Term Debt 0 678 677 676 434
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,415 1,315 1,250 1,209
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,603 3,154 3,032 3,055 2,716
Shareholders Equity 9/30/2022 6/30/2022 3/31/2022 12/31/2021 9/30/2021
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 6,337 6,173 6,117 6,058 5,969
Retained Earnings -6,362 -5,956 -5,679 -5,438 -5,180
Other Equity -44 -42 -38 -33 -34
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -68 176 401 588 756
Total Liabilities & Shareholder's Equity 3,535 3,330 3,434 3,643 3,472
Total Common Equity -68 176 401 588 756
Shares Outstanding 123.00 120.00 120.80 119.60 119.60
Book Value Per Share -0.55 1.47 3.32 4.92 6.32